Literature DB >> 1847316

Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome.

N A Miller1, H A Carmichael, B D Calder, P O Behan, E J Bell, R A McCartney, F C Hall.   

Abstract

OBJECTIVE: To study the association between coxsackie B virus infection and the postviral fatigue syndrome and to assess the immunological abnormalities associated with the syndrome.
DESIGN: Case-control study of patients with the postviral fatigue syndrome referred by local general practitioners over one year.
SETTING: General practitioner referrals in Dunbartonshire, Scotland. PATIENTS: 254 Patients referred with the postviral fatigue syndrome (exhaustion, myalgia, and other symptoms referable to postviral fatigue syndrome of fairly recent onset--that is, several months) and age and sex matched controls obtained from same general practitioner; 11 patients were rejected because of wrong diagnoses, resolution of symptoms, and refusal to participate, leaving 243 patients and matched controls. MAIN OUTCOME MEASURES: Detailed questionnaire (patients and controls) and clinical examination (patients) and blind analysis of blood sample at entry and after six months for determination of coxsackie B virus IgM and IgG antibodies and other variables (including lymphocyte protein synthesis, lymphocyte subsets, and immune complexes).
RESULTS: Percentage positive rates for coxsackie B virus IgM at entry were 24.4% for patients and 22.6% for controls and for coxsackie B virus IgG 56.2% and 55.3% respectively; there were no significant differences between different categories of patients according to clinical likelihood of the syndrome nor any predictive value in a fourfold rise or fall in the coxsackie B virus IgG titre in patients between entry and review at six months. The rates of positive antibody test results in patients and controls showed a strong seasonal variation. Of the numerous immunological tests performed, only a few detected significant abnormalities; in particular the mean value for immune complex concentration was much higher in 35 patients and 35 controls compared with the normal range and mean value for total IgM was also raised in 227 patients and 35 controls compared with the normal range.
CONCLUSIONS: Serological tests available for detecting coxsackie B virus antibodies do not help diagnose the postviral fatigue syndrome. Percentage positive rates of the antibodies in patients simply reflect the background in the population as probably do the raised concentrations of total IgM and immune complexes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847316      PMCID: PMC1668819          DOI: 10.1136/bmj.302.6769.140

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

1.  Epidemic neuromyasthenia; clinical syndrome.

Authors:  D A HENDERSON; A SHELOKOV
Journal:  N Engl J Med       Date:  1959-04-16       Impact factor: 91.245

2.  The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia.

Authors:  E D ACHESON
Journal:  Am J Med       Date:  1959-04       Impact factor: 4.965

3.  Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.

Authors:  S E Straus; G Tosato; G Armstrong; T Lawley; O T Preble; W Henle; R Davey; G Pearson; J Epstein; I Brus
Journal:  Ann Intern Med       Date:  1985-01       Impact factor: 25.391

4.  The postviral fatigue syndrome--an analysis of the findings in 50 cases.

Authors:  P O Behan; W M Behan; E J Bell
Journal:  J Infect       Date:  1985-05       Impact factor: 6.072

5.  Electrophysiological studies in the post-viral fatigue syndrome.

Authors:  G A Jamal; S Hansen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-07       Impact factor: 10.154

6.  Mystery disease at Lake Tahoe challenges virologists and clinicians.

Authors:  D M Barnes
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

Review 7.  Postviral fatigue syndrome.

Authors:  P O Behan; W M Behan
Journal:  Crit Rev Neurobiol       Date:  1988

8.  Routine use of mu-antibody-capture ELISA for the serological diagnosis of Coxsackie B virus infections.

Authors:  R A McCartney; J E Banatvala; E J Bell
Journal:  J Med Virol       Date:  1986-07       Impact factor: 2.327

9.  Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis.

Authors:  L K Borysiewicz; S J Haworth; J Cohen; J Mundin; A Rickinson; J G Sissons
Journal:  Q J Med       Date:  1986-02

10.  Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase.

Authors:  L C Archard; N E Bowles; P O Behan; E J Bell; D Doyle
Journal:  J R Soc Med       Date:  1988-06       Impact factor: 5.344

View more
  17 in total

1.  Outcome in the chronic fatigue syndrome.

Authors:  S Wessely
Journal:  BMJ       Date:  1992-08-08

Review 2.  The chronic fatigue syndrome.

Authors:  D G James; M G Brook; B A Bannister
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

Review 3.  Infectious diseases and AIDS.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

4.  Immune responsiveness in chronic fatigue syndrome.

Authors:  C Shepherd
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 5.  The role of enterovirus in chronic fatigue syndrome.

Authors:  J K S Chia
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

6.  Tired all the time.

Authors:  L Ridsdale
Journal:  BMJ       Date:  1991-12-14

Review 7.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 8.  Chronic fatigue syndrome.

Authors:  S Wessely
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

9.  Coxsackie B virus and postviral fatigue syndrome.

Authors:  P Muir; F Nicholson; J E Banatvala; P J Bingley
Journal:  BMJ       Date:  1991-03-16

Review 10.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.